The 2024 voluntary scheme for branded medicines pricing, access and growth: payment percentage for 2025

AI Summary

This document outlines the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), a collaborative regulatory framework established between the Department of Health and Social Care (DHSC), NHS England, and the Association of the British Pharmaceutical Industry (ABPI). The guidance confirms that the headline payment percentage for participating companies will be set at 22.9% for the 2025 period. Unlike a standard inspection report, this document does not list specific company violations or inspection dates; instead, it provides the financial parameters governing the branded medicines market. The primary objectives of the scheme are to enhance patient health outcomes, foster UK economic growth, and ensure the financial sustainability of the National Health Service (NHS). By establishing these payment levels, the framework requires participating pharmaceutical manufacturers to contribute financially to the healthcare system in exchange for predictable market access. This agreement serves as the foundational mechanism for balancing the costs of innovative treatments with the broader budgetary needs of the public health sector, ensuring that the NHS can continue to provide high-quality care while supporting the domestic life sciences industry.